RT null
T1 Management of Paediatric Ulcerative Colitis, Part 1: Ambulatory Care-An Evidence-based Guideline From European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition.
A1 Turner, Dan
A1 Ruemmele, Frank M
A1 Orlanski-Meyer, Esther
A1 Griffiths, Anne M
A1 de Carpi, Javier Martin
A1 Bronsky, Jiri
A1 Veres, Gabor
A1 Aloi, Marina
A1 Strisciuglio, Caterina
A1 Braegger, Christian P
A1 Assa, Amit
A1 Romano, Claudio
A1 Hussey, Séamus
A1 Stanton, Michael
A1 Pakarinen, Mikko
A1 de Ridder, Lissy
A1 Katsanos, Konstantinos
A1 Croft, Nick
A1 Navas-López, Victor
A1 Wilson, David C
A1 Lawrence, Sally
A1 Russell, Richard K
K1 anti-TNF
K1 calprotectin
K1 children
K1 guidelines
K1 inflammatorybowel disease-unclassified
K1 management
K1 mesalamine
K1 monitoring,pediatrics
K1 Pediatric Ulcerative Colitis Activity Index
K1 thiopurines,treatment
K1 ulcerative colitis
K1 vedolizumab
AB Background: The contemporary management of ambulatory ulcerativecolitis (UC) continues to be challenging with 20% of children needinga colectomy within childhood years. We thus aimed to standardize dailytreatment of pediatric UC and inflammatory bowel diseases (IBD)-unclas-sified through detailed recommendations and practice points.Methods: These guidelines are a joint effort of the European Crohn’s andColitis Organization (ECCO) and the Paediatric IBD Porto group of EuropeanSociety of Paediatric Gastroenterology, Hepatology and Nutrition(ESPGHAN). An extensive literature search with subsequent evidenceappraisal using robust methodology was performed before 2 face-to-facemeetings. All 40 included recommendations and 86 practice points wereendorsed by 43 experts in Paediatric IBD with at least an 88% consensus rate.Results: These guidelines discuss how to optimize the use of mesalamine(including topical), systemic and locally active steroids, thiopurines and, formore severe disease, biologics. The use of other emerging therapies and therole of surgery are also covered. Algorithms are provided to aid therapeuticdecision-making based on clinical assessment and the Paediatric UC ActivityIndex (PUCAI). Advice on contemporary therapeutic targets incorporatingthe use of calprotectin and the role of therapeutic drug monitoring arepresented, as well as other management considerations around pouchitis,extraintestinal manifestations, nutrition, growth, psychology, and transition.A brief section on disease classification using the PIBD-classes criteria andIBD-unclassified is also part of these guidelines.Conclusions: These guidelines provide a guide to clinicians managing childrenwith UC and IBD-unclassified management to provide modern management stra-tegies while maintaining vigilance around appropriate outcomes and safety issues.
PB Wiley
SN 1536-4801
YR 2018
FD 2018-08-01
LK http://hdl.handle.net/10668/12752
UL http://hdl.handle.net/10668/12752
LA en
NO Turner D, Ruemmele FM, Orlanski-Meyer E, Griffiths AM, de Carpi JM, Bronsky J, et al. Management of Paediatric Ulcerative Colitis, Part 1: Ambulatory Care-An Evidence-based Guideline From European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition [published correction appears in J Pediatr Gastroenterol Nutr. 2020 Dec;71(6):794]. J Pediatr Gastroenterol Nutr. 2018;67(2):257-291.
NO This study was supported by European Crohn's and Colitis Organization (ECCO) and the European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN).
DS RISalud
RD Oct 11, 2025